U.S. markets open in 7 hours 21 minutes

CURE Pharmaceutical Holding Corp. (CURR)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.0600-0.1200 (-10.17%)
At close: 3:59PM EDT

CURE Pharmaceutical Holding Corp.

1620 Beacon Place
Oxnard, CA 93033
United States
805 824 0410
http://www.curepharmaceutical.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees18

Key Executives

NameTitlePayExercisedYear Born
Mr. Robert DavidsonPres, CEO & Director196.67kN/A1967
Mr. Michael RedardCFO & Sec.171.03kN/A1959
Mr. Mark Udell CPA, CPAChief Accounting Officer & Treasurer134.41kN/A1977
Dr. Vered Gigi Ph.D.Chief Scientific Officer150.7kN/A1982
Mr. Bhaumik PatelDirector of New TechnologiesN/AN/AN/A
Mr. Jonathan BerlentChief Bus. OfficerN/AN/A1969
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CURE Pharmaceutical Holding Corp., an integrated drug delivery and development company, focuses on improving drug efficacy, safety, and the patient experience through its proprietary drug dosage forms and delivery systems. The company is developing an array of products in cutting-edge delivery platforms and partners with biotech and pharmaceutical companies. It offers CURE 3068 (CUREfilm Sleep), a melatonin-containing sleep aid CUREfilm oral dissolving film (ODF) that is used as a dietary supplement under the brand name ID Life Sleep Strips; and CURE 5079, a sleep aid containing a dietary cannabinoid CUREfilm ODF under the brand name Sleep Stripzzz. The company's products in development stage include CURE 5003 (CUREfilm Blue), a sildenafil CUREfilm ODF, which is in early stage clinical development for the treatment of erectile disorder; CURE 5067 (CUREfilm D), a vitamin D3 CUREfilm ODF for oral administration that is in the optimization development stage; CURE 5200, a CUREfilm ODF substrate; CURE 5209, a CUREfilm ODF for mood enhancement as a dietary supplement; and CURE 5210 (CUREfilm Beta-Caryophyllene), a dietary cannabinoid ODF that is in early feasibility stage to target the CB2 receptor. CURE Pharmaceutical Holding Corp. has a collaboration with Canopy Growth Corporation for the development of low-dose cannabidiol oral thin films. The company was founded in 2011 and is headquartered in Oxnard, California.

Corporate Governance

CURE Pharmaceutical Holding Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.